Media coverage
84
Media coverage
Title Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma Media name/outlet PipelineReview Country/Territory Spain Date 11/12/22 URL www.pipelinereview.com/index.php/2022121182259/Antibodies/Janssen-Presents-New-Data-for-Talquetamab-a-First-in-Class-GPRC5DxCD3-Bispecific-Antibody-Suggesting-Durable-Responses-in-Patients-with-Heavily-Pretreated-Multiple-Myeloma.html Persons Ajai Chari Title Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma Media name/outlet Janssen Country/Territory United States Date 11/12/22 URL https://www.janssen.com/janssen-presents-new-data-talquetamab-first-class-gprc5dxcd3-bispecific-antibody-suggesting-durable Persons Ajai Chari Title Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma Media name/outlet Morningstar.com Country/Territory United States Date 10/12/22 URL https://www.morningstar.com/news/pr-newswire/20221210ny61954/janssen-presents-new-data-for-talquetamab-a-first-in-class-gprc5dxcd3-bispecific-antibody-suggesting-durable-responses-in-patients-with-heavily-pretreated-multiple-myeloma Persons Ajai Chari Title Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma Media name/outlet PR Newswire Country/Territory United States Date 10/12/22 Persons Ajai Chari Title Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma Media name/outlet Street Insider Country/Territory United States Date 10/12/22 URL https://www.streetinsider.com/Press+Releases/Janssen+Presents+New+Data+for+Talquetamab%2C+a+First-in-Class+GPRC5DxCD3+Bispecific+Antibody%2C+Suggesting+Durable+Responses+in+Patients+with+Heavily+Pretreated+Multiple+Myeloma/20954948.html Persons Ajai Chari Title Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma Media name/outlet Yahoo! News Country/Territory United States Date 10/12/22 URL https://www.yahoo.com/now/janssen-presents-data-talquetamab-first-164300350.html Persons Ajai Chari Title Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma Media name/outlet Yahoo! Finance Country/Territory United States Date 10/12/22 URL https://finance.yahoo.com/news/janssen-presents-data-talquetamab-first-164300350.html Persons Ajai Chari Title Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma Media name/outlet ProfitQuotes.com Country/Territory United States Date 10/12/22 URL www.profitquotes.com/cgi/?a=news&ticker=a&w=&story=202212202212101143PR_NEWS_USPR_____NY61954 Persons Ajai Chari Title Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable.. Media name/outlet ADVFN UK Country/Territory United Kingdom Date 10/12/22 URL https://uk.advfn.com/stock-market/share-news/Janssen-Presents-New-Data-for-Talquetamab-a-First/89750475 Persons Ajai Chari Title Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma Media name/outlet TickerTech.com Country/Territory United States Date 10/12/22 URL www.tickertech.com/cgi/?a=news&ticker=a&w=&story=202212202212101143PR_NEWS_USPR_____NY61954 Persons Ajai Chari Title Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma Media name/outlet APNews.com Country/Territory United States Date 10/12/22 URL https://apnews.com/press-release/pr-newswire/health-cancer-european-commission-johnson-and-us-food-drug-administration-d9be2997760a41ca1ba7fb79b1acc427 Persons Ajai Chari Title Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma Media name/outlet ADVFN US Country/Territory United States Date 10/12/22 URL https://www.advfn.com/p.php?pid=nmona&article=89750475 Persons Ajai Chari Title Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma Media name/outlet TD Ameritrade Country/Territory United States Date 10/12/22 URL https://research.tdameritrade.com/grid/public/markets/news/story.asp?fromPage=results&docKey=100-344p7954-1 Persons Ajai Chari Title Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma Media name/outlet Finanzen.ch Country/Territory Switzerland Date 10/12/22 URL https://www.finanzen.ch/nachrichten/aktien/janssen-presents-new-data-for-talquetamab-a-first-in-class-gprc5dxcd3-bispecific-antibody-suggesting-durable-responses-in-patients-with-heavily-pretreated-multiple-myeloma-11981122 Persons Ajai Chari Title Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma Media name/outlet Spoke.com Country/Territory United States Date 10/12/22 URL https://www.spoke.com/press_releases/6394bbe70893f17121010942 Persons Ajai Chari Title Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma Media name/outlet KCBD Country/Territory United States Date 10/12/22 URL www.kcbd.com/prnewswire/2022/12/10/janssen-presents-new-data-talquetamab-first-in-class-gprc5dxcd3-bispecific-antibody-suggesting-durable-responses-patients-with-heavily-pretreated-multiple-myeloma/ Persons Ajai Chari Title Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma Media name/outlet WLOX Country/Territory United States Date 10/12/22 URL https://www.wlox.com/prnewswire/2022/12/10/janssen-presents-new-data-talquetamab-first-in-class-gprc5dxcd3-bispecific-antibody-suggesting-durable-responses-patients-with-heavily-pretreated-multiple-myeloma/ Persons Ajai Chari Title Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma Media name/outlet KKTV.com Country/Territory United States Date 10/12/22 URL https://www.kktv.com/prnewswire/2022/12/10/janssen-presents-new-data-talquetamab-first-in-class-gprc5dxcd3-bispecific-antibody-suggesting-durable-responses-patients-with-heavily-pretreated-multiple-myeloma/ Persons Ajai Chari Title Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma Media name/outlet WBRC Country/Territory United States Date 10/12/22 URL https://www.wbrc.com/prnewswire/2022/12/10/janssen-presents-new-data-talquetamab-first-in-class-gprc5dxcd3-bispecific-antibody-suggesting-durable-responses-patients-with-heavily-pretreated-multiple-myeloma/ Persons Ajai Chari Title Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma Media name/outlet KOLO TV Reno Country/Territory United States Date 10/12/22 URL https://www.kolotv.com/prnewswire/2022/12/10/janssen-presents-new-data-talquetamab-first-in-class-gprc5dxcd3-bispecific-antibody-suggesting-durable-responses-patients-with-heavily-pretreated-multiple-myeloma/ Persons Ajai Chari Title Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma Media name/outlet WSFA Country/Territory United States Date 10/12/22 URL https://www.wsfa.com/prnewswire/2022/12/10/janssen-presents-new-data-talquetamab-first-in-class-gprc5dxcd3-bispecific-antibody-suggesting-durable-responses-patients-with-heavily-pretreated-multiple-myeloma/ Persons Ajai Chari Title Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma Media name/outlet Fox 19 Country/Territory United States Date 10/12/22 URL www.fox19.com/prnewswire/2022/12/10/janssen-presents-new-data-talquetamab-first-in-class-gprc5dxcd3-bispecific-antibody-suggesting-durable-responses-patients-with-heavily-pretreated-multiple-myeloma/ Persons Ajai Chari Title Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma Media name/outlet NewsChannel 10 Country/Territory United States Date 10/12/22 URL www.newschannel10.com/prnewswire/2022/12/10/janssen-presents-new-data-talquetamab-first-in-class-gprc5dxcd3-bispecific-antibody-suggesting-durable-responses-patients-with-heavily-pretreated-multiple-myeloma/ Persons Ajai Chari Title Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma Media name/outlet WSAZ Country/Territory United States Date 10/12/22 URL https://www.wsaz.com/prnewswire/2022/12/10/janssen-presents-new-data-talquetamab-first-in-class-gprc5dxcd3-bispecific-antibody-suggesting-durable-responses-patients-with-heavily-pretreated-multiple-myeloma/ Persons Ajai Chari Title Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma Media name/outlet KYTV Country/Territory United States Date 10/12/22 URL https://www.ky3.com/prnewswire/2022/12/10/janssen-presents-new-data-talquetamab-first-in-class-gprc5dxcd3-bispecific-antibody-suggesting-durable-responses-patients-with-heavily-pretreated-multiple-myeloma/ Persons Ajai Chari Title Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma Media name/outlet NBC12 Online Country/Territory United States Date 10/12/22 URL www.nbc12.com/prnewswire/2022/12/10/janssen-presents-new-data-talquetamab-first-in-class-gprc5dxcd3-bispecific-antibody-suggesting-durable-responses-patients-with-heavily-pretreated-multiple-myeloma/ Persons Ajai Chari Title Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma Media name/outlet Wave 3 Country/Territory United States Date 10/12/22 URL www.wave3.com/prnewswire/2022/12/10/janssen-presents-new-data-talquetamab-first-in-class-gprc5dxcd3-bispecific-antibody-suggesting-durable-responses-patients-with-heavily-pretreated-multiple-myeloma/ Persons Ajai Chari Title Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma Media name/outlet WBKO Country/Territory United States Date 10/12/22 URL https://www.wbko.com/prnewswire/2022/12/10/janssen-presents-new-data-talquetamab-first-in-class-gprc5dxcd3-bispecific-antibody-suggesting-durable-responses-patients-with-heavily-pretreated-multiple-myeloma/ Persons Ajai Chari Title Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma Media name/outlet KWTX Country/Territory United States Date 10/12/22 URL https://www.kwtx.com/prnewswire/2022/12/10/janssen-presents-new-data-talquetamab-first-in-class-gprc5dxcd3-bispecific-antibody-suggesting-durable-responses-patients-with-heavily-pretreated-multiple-myeloma/ Persons Ajai Chari Title Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma Media name/outlet WALB 10 Country/Territory Georgia Date 10/12/22 URL www.walb.com/prnewswire/2022/12/10/janssen-presents-new-data-talquetamab-first-in-class-gprc5dxcd3-bispecific-antibody-suggesting-durable-responses-patients-with-heavily-pretreated-multiple-myeloma/ Persons Ajai Chari Title Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma Media name/outlet Hawaii News Now Country/Territory United States Date 10/12/22 URL www.hawaiinewsnow.com/prnewswire/2022/12/10/janssen-presents-new-data-talquetamab-first-in-class-gprc5dxcd3-bispecific-antibody-suggesting-durable-responses-patients-with-heavily-pretreated-multiple-myeloma/ Persons Ajai Chari Title Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma Media name/outlet KCRG.com Country/Territory United States Date 10/12/22 URL https://www.kcrg.com/prnewswire/2022/12/10/janssen-presents-new-data-talquetamab-first-in-class-gprc5dxcd3-bispecific-antibody-suggesting-durable-responses-patients-with-heavily-pretreated-multiple-myeloma/ Persons Ajai Chari Title Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma Media name/outlet Upper Michigans Source Country/Territory United States Date 10/12/22 URL https://www.uppermichiganssource.com/prnewswire/2022/12/10/janssen-presents-new-data-talquetamab-first-in-class-gprc5dxcd3-bispecific-antibody-suggesting-durable-responses-patients-with-heavily-pretreated-multiple-myeloma/ Persons Ajai Chari Title Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma Media name/outlet WKYT Country/Territory United States Date 10/12/22 URL https://www.wkyt.com/prnewswire/2022/12/10/janssen-presents-new-data-talquetamab-first-in-class-gprc5dxcd3-bispecific-antibody-suggesting-durable-responses-patients-with-heavily-pretreated-multiple-myeloma/ Persons Ajai Chari Title Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma Media name/outlet KBTX.com Country/Territory United States Date 10/12/22 URL https://www.kbtx.com/prnewswire/2022/12/10/janssen-presents-new-data-talquetamab-first-in-class-gprc5dxcd3-bispecific-antibody-suggesting-durable-responses-patients-with-heavily-pretreated-multiple-myeloma/ Persons Ajai Chari Title Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma Media name/outlet NBCNebraskaScottsbluff.com Country/Territory United States Date 10/12/22 URL https://www.nbcnebraskascottsbluff.com/prnewswire/2022/12/10/janssen-presents-new-data-talquetamab-first-in-class-gprc5dxcd3-bispecific-antibody-suggesting-durable-responses-patients-with-heavily-pretreated-multiple-myeloma/ Persons Ajai Chari Title Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma Media name/outlet WVLT Country/Territory United States Date 10/12/22 URL https://www.wvlt.tv/prnewswire/2022/12/10/janssen-presents-new-data-talquetamab-first-in-class-gprc5dxcd3-bispecific-antibody-suggesting-durable-responses-patients-with-heavily-pretreated-multiple-myeloma/ Persons Ajai Chari Title Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Media name/outlet Winchester Sun Country/Territory United States Date 10/12/22 URL https://smb.winchestersun.com/article/Janssen-Presents-New-Data-for-Talquetamab-a-First-in-Class-GPRC5DxCD3-Bispecific-Antibody-Suggesting-Durable-Responses-in-Patients-with-Heavily-Pretreated-Multiple-Myeloma?storyId=6394b827aaf944db5d5a2dd0 Persons Ajai Chari Title Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Media name/outlet Salisbury Post Country/Territory United States Date 10/12/22 URL https://smb.salisburypost.com/article/Janssen-Presents-New-Data-for-Talquetamab-a-First-in-Class-GPRC5DxCD3-Bispecific-Antibody-Suggesting-Durable-Responses-in-Patients-with-Heavily-Pretreated-Multiple-Myeloma?storyId=6394b827aaf944db5d5a2dd0 Persons Ajai Chari Title Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Media name/outlet Smithfield Times Country/Territory United States Date 10/12/22 URL https://smb.smithfieldtimes.com/article/Janssen-Presents-New-Data-for-Talquetamab-a-First-in-Class-GPRC5DxCD3-Bispecific-Antibody-Suggesting-Durable-Responses-in-Patients-with-Heavily-Pretreated-Multiple-Myeloma?storyId=6394b827aaf944db5d5a2dd0 Persons Ajai Chari Title Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Media name/outlet Jessamine Journal Country/Territory United States Date 10/12/22 URL https://smb.jessaminejournal.com/article/Janssen-Presents-New-Data-for-Talquetamab-a-First-in-Class-GPRC5DxCD3-Bispecific-Antibody-Suggesting-Durable-Responses-in-Patients-with-Heavily-Pretreated-Multiple-Myeloma?storyId=6394b827aaf944db5d5a2dd0 Persons Ajai Chari Title Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Media name/outlet Port Arthur News Country/Territory United States Date 10/12/22 URL https://smb.panews.com/article/Janssen-Presents-New-Data-for-Talquetamab-a-First-in-Class-GPRC5DxCD3-Bispecific-Antibody-Suggesting-Durable-Responses-in-Patients-with-Heavily-Pretreated-Multiple-Myeloma?storyId=6394b827aaf944db5d5a2dd0 Persons Ajai Chari Title Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma Media name/outlet CW39 NewsFix Country/Territory United States Date 10/12/22 URL https://cw39.com/business/press-releases/cision/20221210NY61954/janssen-presents-new-data-for-talquetamab-a-first-in-class-gprc5dxcd3-bispecific-antibody-suggesting-durable-responses-in-patients-with-heavily-pretreated-multiple-myeloma/ Persons Ajai Chari Title Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Media name/outlet LaGrange Daily News Country/Territory Georgia Date 10/12/22 URL https://smb.lagrangenews.com/article/Janssen-Presents-New-Data-for-Talquetamab-a-First-in-Class-GPRC5DxCD3-Bispecific-Antibody-Suggesting-Durable-Responses-in-Patients-with-Heavily-Pretreated-Multiple-Myeloma?storyId=6394b827aaf944db5d5a2dd0 Persons Ajai Chari Title Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Media name/outlet Suffolk News Herald Country/Territory United States Date 10/12/22 URL https://smb.suffolknewsherald.com/article/Janssen-Presents-New-Data-for-Talquetamab-a-First-in-Class-GPRC5DxCD3-Bispecific-Antibody-Suggesting-Durable-Responses-in-Patients-with-Heavily-Pretreated-Multiple-Myeloma?storyId=6394b827aaf944db5d5a2dd0 Persons Ajai Chari Title Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Media name/outlet Tryon Daily Bulletin Country/Territory United States Date 10/12/22 URL https://smb.tryondailybulletin.com/article/Janssen-Presents-New-Data-for-Talquetamab-a-First-in-Class-GPRC5DxCD3-Bispecific-Antibody-Suggesting-Durable-Responses-in-Patients-with-Heavily-Pretreated-Multiple-Myeloma?storyId=6394b827aaf944db5d5a2dd0 Persons Ajai Chari Title Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma Media name/outlet WKRN Country/Territory United States Date 10/12/22 URL https://www.wkrn.com/news/business/press-releases/cision/20221210NY61954/janssen-presents-new-data-for-talquetamab-a-first-in-class-gprc5dxcd3-bispecific-antibody-suggesting-durable-responses-in-patients-with-heavily-pretreated-multiple-myeloma/ Persons Ajai Chari Title Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma Media name/outlet KTLA Country/Territory United States Date 10/12/22 URL https://ktla.com/news/business/press-releases/cision/20221210NY61954/janssen-presents-new-data-for-talquetamab-a-first-in-class-gprc5dxcd3-bispecific-antibody-suggesting-durable-responses-in-patients-with-heavily-pretreated-multiple-myeloma/ Persons Ajai Chari Title Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma Media name/outlet Fox 2 Now Country/Territory United States Date 10/12/22 URL https://fox2now.com/news/business/press-releases/cision/20221210NY61954/janssen-presents-new-data-for-talquetamab-a-first-in-class-gprc5dxcd3-bispecific-antibody-suggesting-durable-responses-in-patients-with-heavily-pretreated-multiple-myeloma/ Persons Ajai Chari Title Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma Media name/outlet WKBN 27 First News Country/Territory United States Date 10/12/22 URL https://www.wkbn.com/business/press-releases/cision/20221210NY61954/janssen-presents-new-data-for-talquetamab-a-first-in-class-gprc5dxcd3-bispecific-antibody-suggesting-durable-responses-in-patients-with-heavily-pretreated-multiple-myeloma/ Persons Ajai Chari Title Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma Media name/outlet KRON4 Country/Territory United States Date 10/12/22 URL https://www.kron4.com/news/business/press-releases/cision/20221210NY61954/janssen-presents-new-data-for-talquetamab-a-first-in-class-gprc5dxcd3-bispecific-antibody-suggesting-durable-responses-in-patients-with-heavily-pretreated-multiple-myeloma/ Persons Ajai Chari Title Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma Media name/outlet Fox 16 Country/Territory United States Date 10/12/22 URL https://www.fox16.com/business/press-releases/cision/20221210NY61954/janssen-presents-new-data-for-talquetamab-a-first-in-class-gprc5dxcd3-bispecific-antibody-suggesting-durable-responses-in-patients-with-heavily-pretreated-multiple-myeloma/ Persons Ajai Chari Title Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma Media name/outlet Siouxland Matters Country/Territory United States Date 10/12/22 URL https://www.siouxlandproud.com/business/press-releases/cision/20221210NY61954/janssen-presents-new-data-for-talquetamab-a-first-in-class-gprc5dxcd3-bispecific-antibody-suggesting-durable-responses-in-patients-with-heavily-pretreated-multiple-myeloma/ Persons Ajai Chari Title Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma Media name/outlet NBC4 Columbus Country/Territory United States Date 10/12/22 URL https://www.nbc4i.com/business/press-releases/cision/20221210NY61954/janssen-presents-new-data-for-talquetamab-a-first-in-class-gprc5dxcd3-bispecific-antibody-suggesting-durable-responses-in-patients-with-heavily-pretreated-multiple-myeloma/ Persons Ajai Chari Title Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma Media name/outlet WANE-TV Country/Territory United States Date 10/12/22 URL https://www.wane.com/business/press-releases/cision/20221210NY61954/janssen-presents-new-data-for-talquetamab-a-first-in-class-gprc5dxcd3-bispecific-antibody-suggesting-durable-responses-in-patients-with-heavily-pretreated-multiple-myeloma/ Persons Ajai Chari Title Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma Media name/outlet WTWO Country/Territory United States Date 10/12/22 URL https://www.mywabashvalley.com/business/press-releases/cision/20221210NY61954/janssen-presents-new-data-for-talquetamab-a-first-in-class-gprc5dxcd3-bispecific-antibody-suggesting-durable-responses-in-patients-with-heavily-pretreated-multiple-myeloma/ Persons Ajai Chari Title Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma Media name/outlet WJHL.com Country/Territory United States Date 10/12/22 URL https://www.wjhl.com/business/press-releases/cision/20221210NY61954/janssen-presents-new-data-for-talquetamab-a-first-in-class-gprc5dxcd3-bispecific-antibody-suggesting-durable-responses-in-patients-with-heavily-pretreated-multiple-myeloma/ Persons Ajai Chari Title Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma Media name/outlet YOUR BASIN Country/Territory United States Date 10/12/22 URL https://www.yourbasin.com/business/press-releases/cision/20221210NY61954/janssen-presents-new-data-for-talquetamab-a-first-in-class-gprc5dxcd3-bispecific-antibody-suggesting-durable-responses-in-patients-with-heavily-pretreated-multiple-myeloma/ Persons Ajai Chari Title Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma Media name/outlet WTen.com Country/Territory United States Date 10/12/22 URL https://www.news10.com/business/press-releases/cision/20221210NY61954/janssen-presents-new-data-for-talquetamab-a-first-in-class-gprc5dxcd3-bispecific-antibody-suggesting-durable-responses-in-patients-with-heavily-pretreated-multiple-myeloma/ Persons Ajai Chari Title Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma Media name/outlet WWLP.com Country/Territory United States Date 10/12/22 URL https://www.wwlp.com/news/business/press-releases/cision/20221210NY61954/janssen-presents-new-data-for-talquetamab-a-first-in-class-gprc5dxcd3-bispecific-antibody-suggesting-durable-responses-in-patients-with-heavily-pretreated-multiple-myeloma/ Persons Ajai Chari Title Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma Media name/outlet VB Profiles Country/Territory United States Date 10/12/22 URL https://www.vbprofiles.com/press_releases/6394bbef9a7b144b4787d0f5 Persons Ajai Chari Title Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma Media name/outlet Everything Lubbock Country/Territory United States Date 10/12/22 URL https://www.everythinglubbock.com/business/press-releases/cision/20221210NY61954/janssen-presents-new-data-for-talquetamab-a-first-in-class-gprc5dxcd3-bispecific-antibody-suggesting-durable-responses-in-patients-with-heavily-pretreated-multiple-myeloma/ Persons Ajai Chari Title Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma Media name/outlet KOIN Country/Territory United States Date 10/12/22 URL https://www.koin.com/business/press-releases/cision/20221210NY61954/janssen-presents-new-data-for-talquetamab-a-first-in-class-gprc5dxcd3-bispecific-antibody-suggesting-durable-responses-in-patients-with-heavily-pretreated-multiple-myeloma/ Persons Ajai Chari Title Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma Media name/outlet 8 News Now Country/Territory United States Date 10/12/22 URL https://www.8newsnow.com/news/business/press-releases/cision/20221210NY61954/janssen-presents-new-data-for-talquetamab-a-first-in-class-gprc5dxcd3-bispecific-antibody-suggesting-durable-responses-in-patients-with-heavily-pretreated-multiple-myeloma/ Persons Ajai Chari Title Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma Media name/outlet WRIC TV Country/Territory United States Date 10/12/22 URL https://www.wric.com/news/business/press-releases/cision/20221210NY61954/janssen-presents-new-data-for-talquetamab-a-first-in-class-gprc5dxcd3-bispecific-antibody-suggesting-durable-responses-in-patients-with-heavily-pretreated-multiple-myeloma/ Persons Ajai Chari Title Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma Media name/outlet KFOR.com Country/Territory United States Date 10/12/22 URL https://kfor.com/business/press-releases/cision/20221210NY61954/janssen-presents-new-data-for-talquetamab-a-first-in-class-gprc5dxcd3-bispecific-antibody-suggesting-durable-responses-in-patients-with-heavily-pretreated-multiple-myeloma/ Persons Ajai Chari Title Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma Media name/outlet PIX11 Country/Territory United States Date 10/12/22 URL https://pix11.com/business/press-releases/cision/20221210NY61954/janssen-presents-new-data-for-talquetamab-a-first-in-class-gprc5dxcd3-bispecific-antibody-suggesting-durable-responses-in-patients-with-heavily-pretreated-multiple-myeloma/ Persons Ajai Chari Title Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma Media name/outlet CBS17.com Country/Territory United States Date 10/12/22 URL https://www.cbs17.com/news/business/press-releases/cision/20221210NY61954/janssen-presents-new-data-for-talquetamab-a-first-in-class-gprc5dxcd3-bispecific-antibody-suggesting-durable-responses-in-patients-with-heavily-pretreated-multiple-myeloma/ Persons Ajai Chari Title Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma Media name/outlet FOX5 San Diego Country/Territory United States Date 10/12/22 URL https://fox5sandiego.com/business/press-releases/cision/20221210NY61954/janssen-presents-new-data-for-talquetamab-a-first-in-class-gprc5dxcd3-bispecific-antibody-suggesting-durable-responses-in-patients-with-heavily-pretreated-multiple-myeloma/ Persons Ajai Chari Title Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma Media name/outlet ABC 27 Country/Territory United States Date 10/12/22 URL https://www.abc27.com/news/business/press-releases/cision/20221210NY61954/janssen-presents-new-data-for-talquetamab-a-first-in-class-gprc5dxcd3-bispecific-antibody-suggesting-durable-responses-in-patients-with-heavily-pretreated-multiple-myeloma/ Persons Ajai Chari Title Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma Media name/outlet MyPanhandle.com Country/Territory United States Date 10/12/22 URL https://www.mypanhandle.com/business/press-releases/cision/20221210NY61954/janssen-presents-new-data-for-talquetamab-a-first-in-class-gprc5dxcd3-bispecific-antibody-suggesting-durable-responses-in-patients-with-heavily-pretreated-multiple-myeloma/ Persons Ajai Chari Title Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma Media name/outlet WGNO Country/Territory United States Date 10/12/22 URL https://wgno.com/business/press-releases/cision/20221210NY61954/janssen-presents-new-data-for-talquetamab-a-first-in-class-gprc5dxcd3-bispecific-antibody-suggesting-durable-responses-in-patients-with-heavily-pretreated-multiple-myeloma/ Persons Ajai Chari Title Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma Media name/outlet WIVB Country/Territory United States Date 10/12/22 URL https://www.wivb.com/business/press-releases/cision/20221210NY61954/janssen-presents-new-data-for-talquetamab-a-first-in-class-gprc5dxcd3-bispecific-antibody-suggesting-durable-responses-in-patients-with-heavily-pretreated-multiple-myeloma/ Persons Ajai Chari Title Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma Media name/outlet WGN-TV Country/Territory United States Date 10/12/22 URL https://wgntv.com/business/press-releases/cision/20221210NY61954/janssen-presents-new-data-for-talquetamab-a-first-in-class-gprc5dxcd3-bispecific-antibody-suggesting-durable-responses-in-patients-with-heavily-pretreated-multiple-myeloma/ Persons Ajai Chari Title Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma Media name/outlet FOX8 WGHP Country/Territory United States Date 10/12/22 URL https://myfox8.com/business/press-releases/cision/20221210NY61954/janssen-presents-new-data-for-talquetamab-a-first-in-class-gprc5dxcd3-bispecific-antibody-suggesting-durable-responses-in-patients-with-heavily-pretreated-multiple-myeloma/ Persons Ajai Chari Title Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma Media name/outlet FOX 59 Country/Territory United States Date 10/12/22 URL https://fox59.com/news/business/press-releases/cision/20221210NY61954/janssen-presents-new-data-for-talquetamab-a-first-in-class-gprc5dxcd3-bispecific-antibody-suggesting-durable-responses-in-patients-with-heavily-pretreated-multiple-myeloma/ Persons Ajai Chari Title Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma Media name/outlet WATE Country/Territory United States Date 10/12/22 URL https://www.wate.com/news/business/press-releases/cision/20221210NY61954/janssen-presents-new-data-for-talquetamab-a-first-in-class-gprc5dxcd3-bispecific-antibody-suggesting-durable-responses-in-patients-with-heavily-pretreated-multiple-myeloma/ Persons Ajai Chari Title Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma Media name/outlet WREG Country/Territory United States Date 10/12/22 URL https://wreg.com/business/press-releases/cision/20221210NY61954/janssen-presents-new-data-for-talquetamab-a-first-in-class-gprc5dxcd3-bispecific-antibody-suggesting-durable-responses-in-patients-with-heavily-pretreated-multiple-myeloma/ Persons Ajai Chari Title Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma Media name/outlet FOX 31 News KDVR Country/Territory United States Date 10/12/22 URL https://kdvr.com/news/business/press-releases/cision/20221210NY61954/janssen-presents-new-data-for-talquetamab-a-first-in-class-gprc5dxcd3-bispecific-antibody-suggesting-durable-responses-in-patients-with-heavily-pretreated-multiple-myeloma/ Persons Ajai Chari Title Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma Media name/outlet Fox 4 WDAF TV Country/Territory United States Date 10/12/22 URL https://fox4kc.com/news/business/press-releases/cision/20221210NY61954/janssen-presents-new-data-for-talquetamab-a-first-in-class-gprc5dxcd3-bispecific-antibody-suggesting-durable-responses-in-patients-with-heavily-pretreated-multiple-myeloma/ Persons Ajai Chari Title Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma Media name/outlet Johnson & Johnson Country/Territory United States Date 10/12/22 URL https://www.jnj.com/janssen-presents-new-data-for-talquetamab-a-first-in-class-gprc5dxcd3-bispecific-antibody-suggesting-durable-responses-in-patients-with-heavily-pretreated-multiple-myeloma Persons Ajai Chari Title Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable... Media name/outlet User Walls Country/Territory United States Date 10/12/22 URL https://www.userwalls.news/health/janssen-presents-data-talquetamab-class-gprc5dxcd3-bispecific-antibody-suggesting-durable-responses-patients-5689493/ Persons Ajai Chari Title Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma Media name/outlet KXAN Country/Territory United States Date 10/12/22 URL https://www.kxan.com/business/press-releases/cision/20221210NY61954/janssen-presents-new-data-for-talquetamab-a-first-in-class-gprc5dxcd3-bispecific-antibody-suggesting-durable-responses-in-patients-with-heavily-pretreated-multiple-myeloma/ Persons Ajai Chari Title Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma Media name/outlet Wood TV Country/Territory United States Date 10/12/22 URL https://www.woodtv.com/business/press-releases/cision/20221210NY61954/janssen-presents-new-data-for-talquetamab-a-first-in-class-gprc5dxcd3-bispecific-antibody-suggesting-durable-responses-in-patients-with-heavily-pretreated-multiple-myeloma/ Persons Ajai Chari